AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05007587
Drug: ROX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAIC was performed every 3 weeks. The ROX regimen was administered via hepatic artery: oxaliplatin , 100mg/m2 , from hour 0 to 4 on day1 ;raltitrexed , 3mg/m2 , from hour 4 to 5 on day 1.
Trial: NCT04716426
Drug: Tetracycline hydrochloride 3%
RxNorm normalized name: Tetracycline Hydrochloride 3% Topical application Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprietary formulation composed of FDA approved inactive ingredients and the active pharmaceutical ingredient tetracycline hydrochloride.
Trial: NCT04716426
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation composed of FDA approved inactive ingredients.
Trial: NCT04163536
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in the control group, placebo will be administered intravenously for 5 days. Placebo will be identical (color and aspect) to experimental substance, will be provide as a 50 mL of NaCl 0.9% solution and administered intravenously over 15 minutes, once a day.
Trial: NCT00588926
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the mapping electrode is in situ, recording of baseline electrical activity is done for two-three minutes and an infusion of Remifentanil, 0.1 microgram per kilogram per minute is started. This procedure continues for a few minutes until the patient is sedated and then the infusion is stopped and the patient allowed to recover. The recordings continue during the whole procedure.
Trial: NCT05119998
Drug: IBI325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI325 monotherapy does-escalation Patients will receive IBI325 until progressive disease, intolerability, or other reasons leading to treatment discontinuation
Trial: NCT05018013
Drug: Placebo to Ammoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Ammoxetine
Trial: NCT05706870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06617312
Drug: Cytisinicline
RxNorm normalized name: cytisinicline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targets α4β2 nicotinic acetylcholine receptors
Trial: NCT06617312
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched to active drug, cytisinicline
Trial: NCT05835934
Drug: [14C]HSK21542
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous dose of 2 μg/0.212 μCi/kg \[14C\]HSK21542 in boluses within 2 minute after fasting for at least 10 hours.
Trial: NCT00002036
Drug: Anti-HIV Immune Serum Globulin (Human)
RxNorm normalized name: immune globulin subcutaneous (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05043194
Drug: Ursodeoxycholic Acid 250 Mg Oral Capsule
RxNorm normalized name: Ursodeoxycholic acid 250 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prevention
Trial: NCT05261594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule, oral intake
Trial: NCT04562727
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: perioperative chemotherapy or postoperative chemotherapy
Trial: NCT04493229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IM
Trial: NCT01028443
Drug: Artelose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05299411
Drug: iron (isomaltoside)
RxNorm normalized name: Iron isomaltoside 1000
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iron supplement through intravenous infusion
Trial: NCT04765371
Drug: PREDNISOLONE
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take 60 mg per day of Prednisolone (40 mg morning and 20 md evening) between D1 to D10
Trial: NCT04882826
Drug: Viagra® film-coated tablet 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viagra® is manufactured by Fareva Amboise, France. Each tablet contains 100 mg of sildenafil.
Trial: NCT05466240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 5 days
Trial: NCT05966454
Drug: Multiple standard of care antibiotics for appendicitis, at physicians' discretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care Antibiotic use will be restricted to none or up to 24 hours of post-operative antibiotics.
Trial: NCT05966454
Drug: Multiple standard of care antibiotics for appendicitis, at physicians' discretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care Antibiotic use will be permitted for 24 hours or up to 4 days of post-operative antibiotics.
Trial: NCT05326672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, applied twice daily for 8 weeks after enrolment.
Trial: NCT00664690
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo given preop and BID postop
Trial: NCT05381194
Drug: BPaL(M) regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients diagnosed with MDR/RR-TB are initially assigned to the BPaLM regimen as a single-arm for treatment initiation. Afterward, if MDR/RR-TB is confirmed to be fluoroquinolone-resistant by molecular or phenotypic DST, the treatment is switched to the BPaL regimen (for 24 weeks). On the other hand, if MDR/RR-TB is confirmed to be fluoroquinolone-susceptible, treatment for MDR/RR-TB is maintained with the BPaLM regimen (for 26 weeks).~The dosage of each medication is as follows:~* Bedaquiline 400mg/day for the 2 weeks, 200mg/TIW afterward~* Pretomanid 200mg/day~* Linezolid 600mg/day for the 9weeks, 300mg/day afterward~* Moxifloxacin 400mg/day
Trial: NCT05398055
Drug: Azithromycin + Doxycycline
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin 500 mg orally every 24 hours for three dose plus doxycycline 100 mg orally every 12 hours for 7 days
Trial: NCT05398055
Drug: Placebo + Doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxycycline 100 mg orally every 12 hours for 7 days plus placebo 1 capsule every 24 hours, 3 doses
Trial: NCT00000834
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04646031
Drug: T89 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T89 capsule, an medicinal product for oral use under active INDs in the US is a botanical drug containing 75mg active substance of the water extract of Danshen and Sanqi.
Trial: NCT05241470
Drug: Placebo Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop in each eye twice a day
Trial: NCT05611671
Drug: MORF-057
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
Trial: NCT05611671
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (identical appearance to MORF-057) administered orally.
Trial: NCT05020028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg Placebo ODT looks like the cannabidiol (CBD) Orally Disintegrating Tablets (ODT), but contains no active ingredients.
Trial: NCT06184633
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control arm receives placebo in addition to combined lifestyle intervention
Trial: NCT04802382
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive the placebo treatment in addition to Standard of Care
Trial: NCT04802382
Drug: CimetrA-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive the study treatment, CimetrA-1 treatment in addition to Standard of Care
Trial: NCT04802382
Drug: CimetrA-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive the study treatment, CimetrA-2 treatment in addition to Standard of Care
Trial: NCT03380728
Drug: Ibogaine Hydrochloride
RxNorm normalized name: IBOGAINE HYDROCHLORIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first 3 patients will receive oral doses of 20 to 400 mg of ibogaine in an open-label design. If the 3 higher doses (240, 320 and 400 mg) are well tolerated, the next 9 volunteers will receive these doses or placebo randomly in 3 different groups.
Trial: NCT04921111
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aluminium phosphate
Trial: NCT00737542
Drug: NACL 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05121766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 Soybean Oil Placebo capsules
Trial: NCT05261386
Drug: CBT-008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat MGD
Trial: NCT05359653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched sugar tablet
Trial: NCT06038968
Drug: Methotrexate 25 MG/ML
RxNorm normalized name: methotrexate 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division.
Trial: NCT05067621
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection pen contains excipients.
Trial: NCT05837338
Drug: BXP154
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BXP154 will be self-administered topically following wound induction
Trial: NCT05837338
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be self-administered topically following wound induction
Trial: NCT05372718
Drug: Recombinant non-immunogenic staphylokinase (Fortelyzin®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lyophilisate for preparation a solution
Trial: NCT04980534
Drug: COVID-19 Standard Therapy
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be assigned to receive the standard therapy for COVID-19 disease: Antibiotic, Antivirals, Analgaesic, Anti-inflammatory drugs.
Trial: NCT06025318
Drug: PanCytoVir™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PanCytoVir™ 100 mg/mL oral suspension
Trial: NCT04824274
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 10 mcg will be injected intrathecally during spinal anesthesia.
Trial: NCT06165809
Drug: TQB3015 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3015 is a protein inhibitor
Trial: NCT00000641
Drug: Amikacin sulfate
RxNorm normalized name: Amikacin Sulfate
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00000641
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06372626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride Injection
Trial: NCT04733833
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care
Trial: NCT05990387
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control condition
Trial: NCT05638165
Drug: NCP112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first two subjects for sentinel dosing are randomly assigned to either the test drug or placebo in a 1:1 ratio. After safety and tolerability were reviewed for sentinel participants up to 24 hours after dosing, the subsequent 7 subjects are randomized to the remaining treatment allocations, with 5 subjects to the test drug and 2 to the placebo.
Trial: NCT04859296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaporized placebo
Trial: NCT05763836
Drug: Ibuprofen 800 Mg in 8 mL INTRAVENOUS INJECTION [Caldolor]
RxNorm normalized name: ibuprofen 800 mg in 8 mL INTRAVENOUS INJECTION [Caldolor]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ibuprofen infusion
Trial: NCT06413693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of Placebo administered orally as tablets that look the same as PF-07293893
Trial: NCT04683315
Drug: mFOLFIRINOX Treatment Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).
Trial: NCT06404112
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.
Trial: NCT06404112
Drug: Melantonin Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.
Trial: NCT06196736
Drug: 9MW2821
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle
Trial: NCT06196736
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75mg/m\^2 docetaxel by intravenous infusion or 175 mg/m\^2 paclitaxel by intravenous infusion on day 1 of every 21-day cycle.
Trial: NCT05452525
Drug: CKD-379 I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet administration under fed condition
Trial: NCT05452525
Drug: CKD-379 II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet administration under fed condition
Trial: NCT05452525
Drug: D759+D745+D150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablet coadministration under fed condition
Trial: NCT05104866
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet. Oral route of administration. Active comparator
Trial: NCT06168929
Drug: SHR4640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR4640, 2.5mg\*4 - 10mg\*1
Trial: NCT06168929
Drug: SHR4640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR4640, 10mg\*1 - 2.5mg\*4
Trial: NCT06220214
Drug: Omnipaque 350mgI/mL Solution for Injection
RxNorm normalized name: Omnipaque 350mgI/mL Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of an FDA approved iodinated contrast agent is required to undergo the imaging procedures. It is not the intent of the study to evaluate the contrast agent, but it will be administered at the time of experimental imaging.
Trial: NCT05506540
Drug: ENN0403 1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENN0403 capsules for oral use
Trial: NCT04820686
Drug: AB-729
RxNorm normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.
Trial: NCT05506540
Drug: ENN0403 4mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENN0403 capsules for oral use
Trial: NCT04820686
Drug: SOC NrtI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert.
Trial: NCT05506540
Drug: ENN0403 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENN0403 capsules for oral use
Trial: NCT05506540
Drug: ENN0403 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENN0403 capsules for oral use
Trial: NCT05506540
Drug: ENN0403 30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENN0403 capsules for oral use
Trial: NCT05506540
Drug: ENN0403 20mg (Fed)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENN0403 capsules for oral use
Trial: NCT05506540
Drug: ENN0403 6mg QD X 14 Days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENN0403 capsules for oral use
Trial: NCT05506540
Drug: ENN0403 12mg QD X 14 Days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENN0403 capsules for oral use
Trial: NCT05506540
Drug: ENN0403 20mg QD X 14 Days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENN0403 capsules for oral use
Trial: NCT05506540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules for oral use
Trial: NCT05837455
Drug: Combination anthracycline and/or taxane based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care
Trial: NCT05237752
Drug: LG00034053
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a pan-caspase inhibitor, as a therapeutic agent of osteoarthritis
Trial: NCT05786404
Drug: PRIM-DJ2727 - CAPSULES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with active UC will receive induction dose of 100 grams of stool in orally administered enteric-coated capsules Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727-CAPSULES.These capsules consists of microbiota from well-screened donors. The induction dose of enteric-coated capsules will be derived from 100 grams stool.
Trial: NCT05272683
Drug: GLPG3667
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On day 1 and day 8, participants will receive a single dose
Trial: NCT00002088
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05602493
Drug: Soludronate®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the first visit, the randomized process will take place. Tooth extraction procedure will be performed.
Trial: NCT05602493
Drug: sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile saline
Trial: NCT04588922
Drug: SLS009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection
Trial: NCT06509906
Drug: Fluorouracil (5-FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil will be administered intravenously as per standard of care.
Trial: NCT06486805
Drug: N acetyl cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) is a small molecule containing a thiol (sulfhydryl-containing) group, which has antioxidant properties and is freely filterable, thus making it readily accessible to the intracellular compartment
Trial: NCT05545891
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A drug that contains no medicine
Trial: NCT05901285
Drug: VAX014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumorally administered oncolytic agent comprised of recombinant bacterial minicells. VAX014 is not infectious and is not capable of replication
Trial: NCT05413655
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage form of Placebo is the capsule for oral use
Trial: NCT06175338
Drug: MabThera®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MabThera® 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml)
Trial: NCT04003285
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALLO 0 nM (placebo: loading dose, 4-hour infusion, taper)
Trial: NCT06191848
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo subcutaneously
Trial: NCT05516316
Drug: EP395
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule for oral use
Trial: NCT05516316
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule for oral use
Trial: NCT06044857
Drug: 68-Ga PSMA11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be injected/assessed in line with its FDA label.
Trial: NCT06139211
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabin will be administered orally twice daily from day 1 to 14 every 21 day cycle.
Trial: NCT06040190
Drug: topical placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individuals will be instructed to dissolve half a tablet of placebo medication and hold the saliva near the painful oral sites without swallowing, for 3 minutes and then spit. Tablets will contain magnesium silicate, with the same color and flavor as the test medications. Researchers will provide a total of 32 tablets for each participant.
Trial: NCT05035524
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05800015
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion, Q3W
Trial: NCT06139211
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
Trial: NCT06139211
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
Trial: NCT06088888
Drug: TGRX-678
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are given TGRX-678 tablets orally, once daily, at one of the dose levels as pre-determined for the dose escalation sequence or expansion cohorts.